Abstract:Xue Fang Li, 1 Shi Rong Liu, 2 Jin Jin Li, 1 Ning Liu, 2 Hui Min Li, 3 An Ning Ge, 4 Liang Liang Wang, 5 Xie Min Dong, 1 Hui Wang, 1 Ju Liu, 1 Lin Zhang, 1 Hao Dong Zhang, 1 Wei Gou 1 1 Department of Metabolic Liver Disease, Qingdao Sixth People's Hospital, Qingdao City, Shandong Province, People's Republic of China; 2 Infectious Diseases department, People's Hospital of Qu fu City, Qufu City, Shandong Province, People's Republic of China; 3 Infection Department, Jiaozhou Branch of Shanghai East Hospital Tongji University, Qingdao City, Shandong Province, People's Republic of China; 4 Department of Infectious Diseases, People's Hospital of Rizhao City, Rizhao City, Shandong Province, People's Republic of China; 5 Medical Intervention Department, Qingdao Sixth People's Hospital, Qingdao City, Shandong Province, People's Republic of China Correspondence: Wei Gou, Department of Metabolic Liver Disease, Qingdao Sixth People's Hospital, Qingdao City, Shandong Province, People's Republic of China, Tel +86-15666687727, Fax +86-532-81636699, Email Objective: To investigate the risk factors for the development of portal hypertension in patients with decompensated cirrhosis and analyze their prognosis. Methods: Patients with decompensated cirrhosis who were admitted to our hospital and Qu fu People's Hospital from June 2022 to June 2023 were included in this study. Among them, there were 45 male and 15 female patients, with a median age of 56 (range: 35– 77) years. A comparative analysis was performed between Group A (hepatic venous pressure gradient, HVPG < 16 mmHg) and Group B (HVPG ≥ 16 mmHg) patients, along with various clinical outcomes. Multivariate analysis was conducted to explore the risk factors influencing the occurrence of portal hypertension and adverse prognosis in patients with cirrhosis. Results: In Group A patients with portal hypertension, we observed lower levels of aspartate aminotransferase, laminin, serum hyaluronic acid, type III procollagen N-terminal peptide, total bile acids, and cholylglycine acid compared to Group B. On the other hand, levels of alanine aminotransferase, white blood cells, and serum albumin were higher in Group A than in Group B. These differences between the groups were statistically significant (P < 0.05). Multivariate analysis of the aforementioned risk factors indicated that low white blood cell count, high cholylglycine acid levels, and high serum hyaluronic acid levels were identified as independent risk factors for the occurrence of difficult-to-control complications in decompensated portal hypertension among patients with liver cirrhosis (P < 0.05). Conclusion: Liver cirrhosis patients with portal hypertension and multiple risk factors like low white blood cell count and high liver transaminase levels should be cautious regarding the progression of portal hypertension when combined with splenomegaly, liver fibrosis, and bile stasis, as it often indicates a poor prognosis. Keywords: portal hypertension, white blood cells, glycine cholate, serum hyaluronic acid According to statistics, the number of patients with chronic liver diseases in China, including chronic hepatitis, fatty liver, and cirrhosis, may exceed 447 million in 2020. Cirrhosis, as a major cause of morbidity and mortality in hepatic diseases, affects over 120 million people worldwide. 1 Decompensated cirrhosis serves as a turning point in the prognosis, primarily manifested by complications such as ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, or variceal bleeding. Accurate staging of decompensated cirrhosis can significantly reduce the risk of mortality. 2 Measurement of HVPG is considered the gold standard for assessing portal hypertension, with HVPG ≥ 16 mm Hg indicating a higher likelihood of refractory complications. 3 Although there have been numerous studies on the risk factors for decompensated cirrhosis in patients with liver cirrhosis, there is a paucity of research focused on the risk factors for decompensated cirrhosis with concomitant portal hypertension. In this study, we conducted a retrospective analysis of clinical data from 60 patients with decompensated cirrhosis from our hospital and People's Hospital of Qu fu City. By employing univariate and multivariate logistic regression analysis, we aimed to identify the risk factors for rebleeding in these patients. In this retrospective analysis, we selected patient records meeting our study criteria from the inpatient electronic case systems at Qingdao Sixth People's Hospital and Qu fu Municipal Hospital. All particip -Abstract Truncated-

Interpretation of Portal Hypertensive Bleeding in Cirrhosis:Risk Stratification, Diagnosis and Management:2016 Practice Guidance by the American Association for the Study of Liver Diseases

Treatment Options for Portal Hypertension in the Era of Liver Transplantation

Letter to the Editor: Risk Stratification in Patients with Child‐Pugh B Cirrhosis and Acute Variceal Bleeding

Guidelines for the Management of Esophagogastric Variceal Bleeding in Cirrhotic Portal Hypertension.

The portal hypertension syndrome: etiology, classification, relevance, and animal models

Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases

Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)

[Advances in Basic and Clinical Research on Liver Cirrhosis in 2016].

Reasonable choice of surgical procedures for patients with portal hypertension

Management of Liver Decompensation in Advanced Chronic Liver Disease: Ascites, Hyponatremia, and Gastroesophageal Variceal Bleeding

Prevention for Rebleeding of Esophageal Varices under the Guidance of Hepatic Venous Pressure Gradient

Value of Controlling Low Central Venous Pressure in Variceal Bleeding Due to Cirrhosis of Liver

Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations

Portal vein computed tomography imaging characteristics and their relationship with bleeding risk in patients with liver cirrhosis undergoing interventional therapy

Practicing clinical research and multidisciplinary team management of portal hypertension

Analysis of Factors Influencing Prognosis and Assessment of 60 Cases of Decompensated Cirrhotic Patients with Portal Hypertension

Management of the risk of bleeding and thrombosis in perioperative patients with liver cirrhosis

Chinese Guidelines On The Management Of Liver Cirrhosis (Abbreviated Version)

Clinical Factors That Influence the Outcome of Selective Devascularization in the Treatment of Portal Hypertension.

Hepatic venous pressure gradient affects the efficacy of endoscopic treatment of gastroesophageal varices in hepatitis B cirrhosis

[Pay attention to the diagnosis and treatment of "easily neglected" complications in liver cirrhosis]